Scholar Rock has received reports of scammers posting fake jobs using Scholar Rock’s name or making fraudulent job offers in Scholar Rock’s name. We have contacted several job boards to get fraudulent job postings removed. If you see a job that is supposedly advertised by Scholar Rock, please check its validity by visiting our website and applying directly at our careers page, where we’ve also added some tips on how to protect yourself from those scams. Visit: https://lnkd.in/eNqC_PX
Scholar Rock
Biotechnology
Cambridge, Massachusetts 7,819 followers
Scholar Rock is a biopharmaceutical company that discovers, develops and delivers life-changing therapies
Über uns
Scholar Rock is a biopharmaceutical company that discovers, develops, and delivers life-changing therapies for people with serious diseases that have high unmet need. As a global leader in the biology of the transforming growth factor beta (TGFβ) superfamily of cell proteins and named for the visual resemblance of a scholar rock to protein structures, the clinical-stage company is focused on advancing innovative treatments where protein growth factors are fundamental. Over the past decade, the company has created a pipeline with the potential to advance the standard of care for neuromuscular disease, cardiometabolic disorders, cancer, and other conditions where growth factor-targeted drugs can play a transformational role. Scholar Rock is the only company to show clinical proof of concept for a muscle-targeted treatment in spinal muscular atrophy (SMA). This commitment to unlocking fundamentally different therapeutic approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. By harnessing cutting-edge science in disease spaces that are historically under-addressed through traditional therapies, Scholar Rock works every day to create new possibilities for patients. Learn more about the company’s approach at ScholarRock.com and follow @ScholarRock and on LinkedIn. For additional information on our guidelines, please visit https://scholarrock.com/community-guidelines/ For more information on how Scholar Rock collects, uses, and shares personal information, please visit: https://scholarrock.com/privacy-policy/
- Website
-
https://scholarrock.com
External link for Scholar Rock
- Industrie
- Biotechnology
- Größe des Unternehmens
- 51-200 Mitarbeiter
- Hauptsitz
- Cambridge, Massachusetts
- Typ
- Öffentliches Unternehmen
- Gegründet
- 2012
Standorte
-
Primäre
Wegbeschreibung erhalten
301 Binney St
Cambridge, Massachusetts 02142, US
Employees at Scholar Rock
-
Peter McLaughlin
VP of IT at Scholar Rock
-
Kerry Costello
Vice President @ Scholar Rock | Program Leadership, Strategy
-
Jing Marantz, MD PhD
Physician-Scientist | CMO | Board Member
-
Jim Zhang
Head of Regulatory Operations | Building sustainable and scalable Reg Ops infrastructure for biotech startup and small pharmaceuticals
Aktualisierungen
-
Jilli is a high school student living with #SMA who dreams of performing on Broadway. Our mission as a company is working towards #CreatingPossibilities for Jilli and others living with SMA who are working hard to make their dreams come true. #SMAAwarenessMonth
-
Here at Scholar Rock, we focus on #CreatingPossibilities by living our values every day. Our first value is to focus on the patient, and we're honoring that during #SMAAwarenessMonth with a focus on SMA community perspectives. Watch as Amy, a mother of children living with #SMA, shares her hopes for the possibilities awaiting her family in the future.
-
This #SMAAwarenessMonth, we join the Muscular Dystrophy Association in celebrating the resilience and strength of the SMA community. MDA is dedicated to empowering people living with #SMA through access to comprehensive care and resources. Learn more: https://lnkd.in/egUzPn2f
-
-
SMA is a diagnosis, not a definition. We are committed to #CreatingPossibilities through our science and highlighting the hopes, needs, and experiences of the #SMA community. #SMAAwarenessMonth
-
-
Scholar Rock recently hosted Brad Loncar and BiotechTV to discuss how we are applying a highly selective approach to growth factor targeting across our pipeline. Our President & CEO, Dr. Jay Backstrom, shared his enthusiasm on the therapeutic potential of our pipeline and the significance of creating additional benefit for patients. Watch more here: https://lnkd.in/g-Frd3iF
𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: Scholar Rock's CEO Jay Backstrom on a big phase 3 readout coming later this year in SMA, myostatin inhibition for obesity, and more. He describes the company's approach of targeting the latent form of growth factors, the importance of the upcoming SAPPHIRE phase 3 readout, the rational for myostatin inhibition in obesity, and recent ASCO data. Full video: https://lnkd.in/g-Frd3iF BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
-
Scholar Rock is pleased to share 48-month data from our TOPAZ trial of our investigational treatment, apitegromab, in SMA. Data from our Phase 3 SAPPHIRE trial is expected to read out in Q4 2024. Learn more: https://lnkd.in/eTFEEwDv
Scholar Rock Reports Second Quarter 2024 Financial Results and Highlights Business Progress | Scholar Rock, Inc.
investors.scholarrock.com
-
August is #SMAAwarenessMonth! Throughout the month we'll be spotlighting voices from the SMA community that motivate us in our work to advance our muscle-targeted approach and create possibilities for people whose lives have been affected by #SMA.
-
-
Happy #NationalInternDay to our fantastic co-ops and summer interns! We’re lucky to have you at Scholar Rock and appreciate your curiosity, hard work and commitment to #CreatingPossibilities for patients.
-
-
Frontiers in Neurology recently published 36-month data from our Phase 2 TOPAZ study. These data further characterize the long-term safety and efficacy profile, and inform our Phase 3 SAPPHIRE trial, which is expected to report topline data in Q4 2024. Read more: https://bit.ly/3Ywr2Ej
-
Verbundene Seiten
Ähnliche Seiten
Jobs durchsuchen
Finanzierung
Scholar Rock
6 total rounds
Siehe mehr Informationen auf crunchbase
Letzte Runde
Eigenkapital nach dem IPO
Externer Crunchbase Link für die letzte Finanzierungsrunde
US$ 85.0M